Source:http://linkedlifedata.com/resource/pubmed/id/20081878
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
2010-9-8
|
pubmed:abstractText |
GVHD remains a major source of morbidity and mortality after allogeneic BMT. GVHD is mediated by alloreactive T cells derived from the hematopoietic graft that target host tissues. Pre-clinical models have shown that presentation of alloantigens by host DCs results in the activation of donor-derived T cells that mediate GVHD. Strategies that interfere with the Ag-presenting capacity of DCs after allogeneic transplantation may decrease the risk of developing GVHD. Vitamin D is a hormone essential for calcium metabolism that shows immunomodulatory properties. We showed that correction of vitamin D deficiency appeared to mitigate manifestations of GVHD. In pre-clinical studies, we have shown that vitamin D inhibits DC maturation, polarizes T-cell populations toward the expression of Th2 as compared with Th1 cytokines, and blunts allogeneic T-cell proliferation in response to DC stimulation. Exposure to vitamin D resulted in increased expression of IDO, an enzyme responsible for tryptophan metabolism that is upregulated in tolerizing DCs. These data suggest that exposure to vitamin D results in immature DC populations that bias toward tolerizing rather than stimulatory T-cell populations. Vitamin D may therefore have a role in the prevention of GVHD.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1476-5365
|
pubmed:author |
pubmed-author:AhmadRR,
pubmed-author:AviganDD,
pubmed-author:BissonnetteAA,
pubmed-author:BoussiotisVV,
pubmed-author:GlotzbeckerBB,
pubmed-author:JoyceRR,
pubmed-author:KeefeWW,
pubmed-author:KufeDD,
pubmed-author:LevineJ DJD,
pubmed-author:MillsHH,
pubmed-author:RosenblattJJ,
pubmed-author:StevensonKK,
pubmed-author:TzachanisDD,
pubmed-author:VasirBB,
pubmed-author:WuZZ,
pubmed-author:ZarwanCC
|
pubmed:issnType |
Electronic
|
pubmed:volume |
45
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1463-8
|
pubmed:meshHeading |
pubmed-meshheading:20081878-Cell Polarity,
pubmed-meshheading:20081878-Cells, Cultured,
pubmed-meshheading:20081878-Dendritic Cells,
pubmed-meshheading:20081878-Graft vs Host Disease,
pubmed-meshheading:20081878-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:20081878-Humans,
pubmed-meshheading:20081878-Immunologic Factors,
pubmed-meshheading:20081878-Immunophenotyping,
pubmed-meshheading:20081878-Mitogens,
pubmed-meshheading:20081878-Signal Transduction,
pubmed-meshheading:20081878-T-Lymphocytes,
pubmed-meshheading:20081878-Vitamin D
|
pubmed:year |
2010
|
pubmed:articleTitle |
Immunomodulatory effects of vitamin D: implications for GVHD.
|
pubmed:affiliation |
Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. jrosenb1@bidmc.harvard.edu
|
pubmed:publicationType |
Journal Article
|